PDCD1 and neoplasm: In lung tumor mouse models, TTFields combined with anti‐PD‐1, anti‐CTLA‐4 (cytotoxic T lymphocyte antigen 4), or anti‐PD‐L1 antibodies reduced tumor volume more effectively than monotherapies.